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Preface
The Nordic Council is an intergovernmental collaborative body for the five countries,
Denmark, Finland, Iceland, Norway and Sweden. One of the committees, the Nordic Senior
Executive Committee for Occupational Environmental Matters, initiated a project in order to
produce criteria documents to be used by the regulatory authorities in the Nordic countries as
a scientific basis for the setting of national occupational exposure limits.
The management of the project is given to an expert group. At present the Nordic Expert
Group consists of the following member:
Vidir Kristjansson Administration of Occupational, Safety and Health,
Iceland
Petter Kristensen National Institute of Occupational Health, Norway
Per Lundberg (chairman) National Institute for Working Life, Sweden
Vesa Riihimäki Institute of Occupational Health, Finland
Leif Simonsen National Institute of Occupational Health, Denmark
For each document an author is appointed by the Expert Group and the national member
acts as a referent. The author searches for literature in different data bases such as Toxline,
Medline, Cancerlit and Nioshtic. Information from other sources such as WHO, NIOSH and
the Dutch Expert Committee is also used as are handbooks such as Patty's Industrial
Hygiene and Toxicology. Evaluation is made of all relevant scientific original literature
found. In exceptional cases information from documents difficult to access are used. The
draft document is discussed within the Expert Group and is finally accepted as the Group's
document.
Editorial work is performed by the Group's Scientific Secretary, Gregory Moore/Johan
Montelius, and technical editing by Ms Karin Sundström, at the National Institute for
Working Life in Sweden.
Only literature judged as reliable and relevant for the discussion is referred to in this
document. Concentrations in air are given in mg/m3 and in biological media in mol/l. In case
they are otherwise given in the original papers they are if possible recalculated and the
original values are given within brackets.
The documents aim at establishing a dose-response / dose-effect relationship and defining
a critical effect based only on the scientific literature. The task is not to give a proposal for a
numerical occupational exposure limit value.
The evaluation of the literature and the drafting of this document on Antimony was made
by Drs John Erik Berg and Knut Skyberg at the Department of Occupational Medicine,
National Institute of Occupational Health, Oslo, Norway. The final version was accepted by
the Nordic Expert Group November 21, 1997, as its document.
We acknowledge the Nordic Council for its financial support of this project.
Gregory Moore/Johan Montelius Per Lundberg
Scientific Secretary Chairman
Abbreviations
AAS Atomic absorption spectrophotometry
ACGIH American Conference of Governmental and Industrial Hygienist
AES Atomic emission spectroscopy
APT Antimony potassium tartrate
ECG Electrocardiogram
BW Body weight
ETAAS Electrothermal atomic absorption spectrometry
GABA g -Aminobutyric acid
GSH Glutathione
IAEA International Atomic Energy Association
IARC International Agency for Research on Cancer
ICP-AES Inductively coupled plasma atomic emission spectrometry
ILO International Labour Office
LD50 Dose that is estimated to be lethal to 50% of test animals
LOAEL Lowest Observable Adverse Effect Level
NAA Neutron activation analysis
NIOSH US National Institute for Occupational Safety and Health
NOAEL No Observable Adverse Effect Level
OEL Occupational exposure limit
PIXE Particle-induced X-ray emission analysis
SFC Supercritical fluid chromatography
TWA Time-weighted average
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11. Introduction
Antimony is an elementary metal, but mined mostly as antimony sulphide
(stibnite). Antimony sulphide is known to be used as a cosmetic, like face
painting, since 4000 BC (103). From biblical times up until the 20th century, it
has also been used in therapeutic drugs. Because of its high toxicity and lack of
efficacy, the medical use in humans was prohibited in the sixteenth century (68).
It was reintroduced in 1657 because King Louis XIV appeared to have been
successfully treated for typhoid fever with an antimony preparation given by a
quack. During the following 200 years, however, antimony had quite widespread
use in pharmacology, for the treatment of syphilis, fever and melancholy. James’s
powder was used against fever and in epilepsy, and contained one part oxide of
antimony and two parts phosphate of lime. Hutchinson recommended the external
use of potassium antimony tartrate for rheumatism. In the mid 1850s antimony
was used to facilitate labour. During the American Civil War antimony became
unpopular because of its irritating action on intestinal mucosa. The anthro-
posophical movement has used antimony mainly due to its founder’s (Rudolf
Steiner) misinterpretation of Paracelsus’ writing. Anthroposophical medicines
containing as much as 5% of antimony are still sold in the UK.
The total world reserves of antimony were estimated in 1988 to be 4.35 million
metric tons, the half of which in China (72). The leading producers are Bolivia
and South Africa (103). Antimony is found in 114 minerals. Pure antimony has
few applications, but alloys are used for instance with lead as grid alloy in storage
batteries, as tank linings, foil, bullets and in cable sheaths. Non-metal compounds
of antimony are used as flame retardant, as pigment in paints and as a glass-
forming substance. Antimony still is a component in antiparasitic medicine
(Triostam, Pentostam). Antimony has no known essential biological function in
living organisms (96).
In an old study of antimony trioxide workers Sir Thomas Oliver reported on 6
workers engaged in the production for a mean of 10 years (73). He observed skin
affection only in two men, in spite of handling the antimony trioxide with bare
hands. Sickness absence was no problem. His conclusion, thus, was that industrial
production of antimony represented no hygienic problem or risk, a statement
which today at least would have to be moderated.
The first description of adverse effects of antimony in man, i.e. in a chemist,
was reported by Ramazzini in 1713 (103).
2. Substance Identification
Antimony or stibium (atomic symbol Sb) is an element, and belongs to group V.
Antimony’s atomic number is 51 and has an atomic weight of 121.75. The outer
2electron shell contains 5 electrons, and the oxidation states of antimony are 0, +3
and +5.
Antimony occurs in its elemental form and in several compounds and alloys.
The most common compounds are oxides, sulphides and hydride (see Table 1).
The most common alloys of antimony are in combination with lead, tin and
copper but alloys with other metals occur.
3. Physical and Chemical Properties
Pure antimony is a silver white, brittle, hard metal, which is easily pulverised
(103). The crystal structure is hexagonal. The density is 6.68 at 25oC. It is soluble
in hot concentrated H2SO4 and in aqua regia (HCl/HNO3 in a 3:1 mixture). The
physical and chemical properties of some antimony compounds are given in
Table 2. Antimony is only slowly oxidised in moist air forming a blackish-grey
mixture of antimony and antimony oxide. Antimony metal burns in air or oxygen
with a red heat with incandescence forming white vapour of antimony trioxide.
This vapour has a garlic-like smell.
Antimony pentaoxide is an oxidising agent which is converted to its trivalent
form in acidic media (103).
Antimony-lead alloys have a high corrosion resistance to many chemicals. A
lead oxide and carbonate protective coat is formed upon exposure to air rendering
the alloy practically inert to further chemical reaction with the atmosphere.
Table 1. Substance identification of antimony and some inorganic compounds.
Chemical abstract name Molecular
formula
CAS registry
number
Molecular
weight
Antimony Sb 7440-36-0 121.75
Antimony hydride (stibine) SbH3 7803-52-3 124.78
Antimony trifluoride SbF3 7783-56-4 178.75
Antimony pentafluoride SbF5 7783-70-2 216.75
Antimony trichloride SbCl3 10025-91-9 228.11
Antimony pentachloride SbCl5 7647-18-9 299.00
Antimony trioxide Sb2O3 1309-64-4 291.50
Antimony pentoxide Sb2O5 1314-60-9 323.50
Antimony orange Sb2S3 1345-04-6 339.68
Stibnite Sb2S3 7446-32-4 339.68
Antimony pentasulphide Sb2S5 1315-04-4 403.80
Antimony tribromide SbBr3 7789-61-9 361.48
Stibnite is a naturally occurring form of diantimony trisulphide which is black and has an
orthorhombic crystal structure, whereas, for instance, while Sb2S3 in the form of antimony orange
is yellow red and has an amorphous structure.
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4Antimony hydride, stibine, is a colourless gas at room temperature with an
unpleasant smell. In the presence of other gases such as hydrogen, stibine
decomposes to hydrogen and minute particles of antimony metal suspended in the
gaseous phase (22). Eventually a mirror or film of antimony is formed on the
walls of the container. If sufficient oxygen is also present, particles of less than
5 m m are formed producing a white deposit. This deposit consists of antimony
trioxide with some higher oxides in smaller quantities.
4. Occurrence, Production and Use
Antimony occurs as stibnite (antimony sulphide) and as a common impurity in
quartz. Only stibnite is mined to produce antimony. The main producing countries
are Bolivia, South Africa and China. Stibnite has also been mined in England but
this activity has been discontinued.
Antimony is processed from stibnite by roasting the sulphide ore in gas-fired
furnaces to produce an oxide fume (see Fig. 1). In addition to mining, a large
amount of the metal is obtained from recycling processes, mostly of batteries.
Antimony-lead is the most common alloy of antimony. Chemically all propor-
tions are possible, however, commercially the lower percentages (1-10% of
antimony) are produced.
Sulphidic ores
and concentrates
Roasting
process Collector 
Refining  
process Collector 
Packaging 
& blending
Finished  
antimony oxides 
Fig. 1. The production process of antimony oxides. Reproduced from ref. (65).
5In industry metals containing antimony are used in storage batteries, solder
metal, cable sheathing, electrodes, printing metals and ammunition. High purity
antimony is used in semiconductors and thermoelectric devices, and in glass indu-
stry. Since early in the 20th century antimony trioxide has been used as a white
pigment for paint. Currently antimony oxide combined with a halide such as chlo-
rine has a widespread use as a flame retardant (76), for instance in textiles (54).
Organic antimony salts are still used in pharmacological preparations for
schistosomiasis and leishmaniasis. A pentavalent antimony derivative produced
by the reaction of stibonic and gluconic acids, is considered the drug of choice in
the treatment of leishmaniasis (81). The historic use of trivalent antimony as an
emetic or expectorant is now obsolete.
5. Occupational Exposure and Uptake
There are numerous occupations in which exposure to antimony takes place.
Miners, smelter and refinery workers have not only been exposed to dust and
fumes from metal antimony and antimony sulphide, but often arsenic and lead.
Refinery workers are also exposed to antimony trioxide fumes. Workers using
antimony-containing metal alloys, such as storage battery workers, may be
exposed to dust from antimony and lead, and stibine and arsine. The gas stibine
may evolve during charging of lead batteries, and thus present an occupational
hazard in closed atmospheres, as the gas is considered poisonous. When textiles,
cables and paints are produced which include antimony trioxide based flame
retardants, workers may be exposed to antimony trioxide.
Occupational exposure levels of antimony have been well documented during
battery production. During smelter work exposure levels of 1-10 mg/m3 of
antimony-containing dust are given in a review article on antimony (103), for
further details see Table 3.
Table 3. Stibine and antimony dust concentrations in work room air
Range (mg/m3) n Ref.
Stibine
Battery production <0.01 - 2.5 10 (46)
Battery production <0.0004 - 0.0068 12 (75)
Battery production 0.04* 150 (41)
Antimony dust
Smelter 0.4 - 70.7 31 (80)
Smelter 0.081 - 138 28 (17)
Smelter 6.9 - 83** 3 (77)
Smelter 5.9* not given (61)
n = number of measurements
* mean value
** recalculated from total dust measurements and chemical analysis
6In a study of US refinery workers Renes reported a concentration of antimony
in the air of 0.40 - 70.7 mg/m3, with a mean concentration of 10.07 - 11.81 mg/m3
(80). One year later, following the improvement of hygienic practices, the levels
were decreased to 0.23 - 37.00 mg/m3 with a mean value of 4.69 - 8.23 mg/m3. In
another study of US refinery workers, Cooper et al. reported levels of 0.081-
138 mg/m3. However, the analytical procedures used were not documented in this
study (17). In a study of Yugoslavic smelter workers Potkonjak and Pavlovich
summarised the total measured dust concentrations to range from 17 to 86 mg/m3.
The total dust consisted of Sb203 (38.7-88.9%) and to a lesser extent Sb205 (2.1-
7.8%) (77, 78). Arsenic oxide was also present.
In a historical overview, McCallum (65) refers to measurements made at a
refinery in the UK before and after the adaptation of technical process
improvements. Before the improvements the measured levels exceeded the
current occupational exposure limit (OEL) of 0.5 mg/m3 (time-weighted average
level), however, after improvements the background levels were around the OEL
although personal sampling in some instances gave levels exceeding the OEL.
Data have not been found for the concentration of antimony in human
biological fluids after stibine exposure; however, data from a lead-acid battery
plant in Norway indicate that levels in the blood are up to 90 m g/l (72).
6. Sampling and Analysis
NIOSH (1978) recommended in the "criteria for a recommended standard -
occupational exposure to antimony" that particulate antimony and compounds
should be sampled using personal sampling pump equipment (54). Dust should be
collected in a filter cassette containing an 0.8 mm cellulose ester membrane filter
(Millipore type AA or equivalent) supported by a cellulose backup pad. A sample
should be collected for an adequate time period to ensure that at least 2.5 m g Sb is
present in the sample. Analysis of the particular matter is done by digesting in a
mixture of acids followed by electrothermal atomic absorption spectrometry
(ETAAS). For volatile antimony compounds, like stibine, an impinger containing
an absorbing solution made of 50 g mercuric chloride dissolved in 1 litre of 6 M
hydrochloric acid is recommended. The solutions are analysed directly without
pre-treatment. The lowest air concentration of stibine that may be measured using
the ETAAS method has been reported to be 0.07 mg/m3 (19). Using inductively
coupled plasma atomic emission spectrometry (ICP-AES) a detection limit of
0.001 mg/m3 for stibine may be obtained (41).
Breathing zone air may be collected during a whole shift through a 0,8 mm
Millipore filter, type AAWPO3700 (Molsheim, France) using a personal battery
operated pump at a flow rate of 1 l/minute (6). The filter must be mineralised in
HNO3 in the presence of 1 mg nickel. The concentration of Sb may be measured
by atomic absorption spectrometry.
The current methods of Sb analysis used are neutron activation analysis (NAA)
and electrothermal atomic absorption spectrometry (ETAAS). The latter method
7is described as being very sensitive (72), but chemical interference from other
metals can occur. NAA is a sensitive technique which can detect several other
elements. Results may, however, be inconsistent when the samples are
contaminated with quartz. The detection limit for both methods is in the order of
10-100 pg.
NAA is also used by forensic investigators to determine the antimony content
present as contaminant in lead bullets (16).
Laintz et al. has described supercritical fluid chromatography (SFC) as a
method for simultaneous determination of arsenic and antimony in environmental
samples (53). Trivalent antimony is extracted with lithium bis(trifluoroethyl)-
dithiocarbamate followed by chromatography. Pentavalent antimony is extracted
after reduction with potassium iodide and sodium thiosulphate. A detection limit
of 11 pg Sb is possible with this method.
7. Toxicokinetics
Absorption, distribution and elimination of organic salts of antimony has been
well documented both in humans and in laboratory animals (33). Studies on
inhalation of inorganic antimony in the occupational setting are not well
documented. Inconsistent results have been reported by different investigations
and may reflect inadequate sampling and sample handling or defective analysis
(96). Variation in the control of contamination in the work place studies is
probably a major explanation. This inconsistency is, however, not confined to the
measurement of antimony, but is a general problem when analysing trace
elements in human body fluids (86). Levels of antimony found in the plasma or
serum analysed by NAA are given in Table 4. This information concerns
occupational studies to mixed exposures, and therefore provides only limited and
indirect information on toxicokinetics of the different forms of antimony in
humans.
Table 4. Plasma or serum antimony concentrations found by neutron activation analysis
of human blood in occupational studies
Mean(SD) m g/l Number of subjects Reference*
0.52(0.19) 7 (47)
0.75(0.51) 8 (99)
2.50(1.37) 149 (48)
3.30(2.70) 4 (8)
5.20** 9 (32)
*Partly reproduced from (96).
**Range 1.0-15 m g/ml.
87.1 Uptake
7.1.1 Oral
In animals organic salts of antimony are slowly absorbed via the gastrointestinal
tract (21). The slow intestinal absorption of organic salts may be due to their
strong irritant effect on the mucosa (91). Metal antimony is poorly absorbed from
the gastrointestinal tract (15).
7.1.2 Inhalation
Bulmer and Johnston (15) refer a study with guinea pigs (unspecified number and
sex)(20) which were exposed to an atmosphere containing 45.4 mg/m3 antimony
trioxide for several weeks. Detailed lenght of exposure period was not given, but
total exposure times of 33-609 hours were calculated, and daily exposure time
was 2 hours during the first two weeks and later 3 hours a day. The amount
entering the body by the respiratory tract varied from 13 to 424 mg. In a more
recent inhalation study on antimony trioxide, rats were exposed at levels of 0.25 -
23.46 mg/m3 for 13 weeks, Sb2O3 accumulated in the lungs, not reaching a steady
state during the exposure period (71).
7.2 Distribution
7.2.1 Human
The background levels of antimony in human organs vary greatly, dependent on
the method of analysis used (Table 5). Some of the variations may depend on the
amount of oxides, sulphides or hydrides of antimony present in the human organ
samples. In an in vitro study, trivalent antimony was found to be bound to red
blood cells to a greater extent than pentavalent antimony (97). More than 10% of
an initial dose of trivalent antimony was still bound to red blood cells incubated in
vitro after 24 hours, whereas pentavalent antimony, the active agent of some
antiparasitic drugs, was hardly bound to red blood cells. It has been suggested that
trivalent antimony may be exchanged with trivalent iron of haemoglobin, or that it
becomes attached to the globin moiety of haemoglobin. At present, the mode of
binding remains unknown.
Antimony trioxide dust has in vivo been detected in lungs by X-ray
spectrophotometry in 113 antimony process workers (67).
Analysis conducted on the autopsied femurs of smelter and refinery workers in
Northern Sweden revealed several metals (59). The analytical techniques
employed were atomic absorption spectrophotometry (AAS), NAA, and particle-
induced X-ray emission analysis (PIXE) in a proton microprobe. The median
level of bone Sb among 7-8 workers was 0.015 (range <0.02 - 0.58) ppm, and
0.007 (range 0.007 - 0.1) ppm in a control group of 3-5 nonexposed workers. The
values suggest some deposition of antimony in human bones.
9Table 5. Background levels of antimony in human biological material (wet weight) from
non occupational exposed individuals.
Organ or tissue Values in several studies
range mean value(s) *
Blood (m g/l) ND - 33 000 0,7 - 85
Urine ( m g/l) ND - 11 <1.0 - 6.2
Serum ( m g/l) ND - 15 <0.6 - 5.2
Liver (mg/kg) <0.01 - 0.07 0.006 - 0.023
Lung (mg/kg) <0.01 - 0.20 0.017 - 0.095
Hair (mg/kg) ND - 2.64 0.041
Teeth (mg/kg) 0.005 - 0.67 not given
* mean values not given for all studies included in the range column
ND = not detectable
Based on information in ref. (72)
The deposition of antimony in the enamel of teeth has been studied in humans
(79). Teeth examined from persons who lived at different periods in time, from
Neolithic age, Roman iron age, Viking age and up to present time have been
examined. Antimony levels below 0.032 m g/g enamel were detected in teeth from
Neolithic man, increasing to 1.59 m g/g in the middle age man, and decreasing to
less than 0.006 m g/g at present time.
In a study of workers at a copper mine and of children living in the vicinity, the
content of antimony in hair was not significantly different between the two groups
(44).
Liebich et al. measured Sb in the hair of welders by NAA, but did not report
their findings, may be due to low levels of antimony compounds in welding
materials (58).
7.2.2 Animal
A single sub-lethal unlabelled dose of approximately 0.035 mg Sb/g tissue as the
pentavalent organic antimony compound di-ethylamine paraamino-phenyl stibiate
was given intravenously to a monkey. The animal was sacrificed 20 minutes after.
The following distribution of antimony was found: spleen (0.12 mg Sb/g tissue),
heart (0.4 mg/g), liver (1.5 mg/g), lungs (2.4 mg/g) and kidneys (7.5 mg/g). Brain
content was not given for this experiment, but either trace or non-detectable
amounts were found in the other monkey experiments with pentavalent organic
antimony (11).
The distribution of 2% Sb2O3 (unlabelled) fed to rats for eight months was
highest in the thyroid glad (mean = 156 m g/g) followed by the liver (mean =
16 m g/g) and spleen (mean =8 m g/g) (34). The amount of antimony in lungs, heart
and kidney was lower.
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The effect of antimony on cardiac muscle has been a concern. A progressive
decrease in the contractile force of the heart after perfusion with 10-15 mg per kg
heart weight was observed in a study on dogs. The decrease was not reversible
following perfusion with antimony-free oxygenated blood. This effect may be
explained if some antimony had been irreversibly bound to the myocardium
during perfusion (14).
7.3 Biotransformation
Inorganic trivalent antimony is not methylated in vivo. A considerable proportion
of the antimony enters the enterohepatic circulation.
The hepatobiliary transport of trivalent antimony is gluthatione dependent in
the same manner as the transport of trivalent arsenic (6). Administration of
trivalent antimony thus increases biliary excretion of gluthatione, indicating that
antimony may compromise conjugation of xenobiotics.
Studies in rats indicate that antimony potassium tartrate (25-100 m mol/kg)
given intravenously, as also bismuth and arsenic compounds, increases the biliary
excretion of non-protein thiols up to 50-fold (39). This was a result of increased
hepatobiliary transport of gluthatione. Administration of antimony decreased
hepatic gluthatione levels by 30%, and also reduced gluthatione conjugation.
Probably antimony is transported as unstable gluthatione complexes.
7.4 Elimination
7.4.1 Excretion in the urine and faeces
Inorganic trivalent antimony is excreted in the urine and via the bile as a GSH
conjugate to the faeces (Table 6). Trivalent antimony is equally excreted by the
faeces, and in the urine, whereas pentavalent antimony is mainly excreted by the
renal route (6). Antimony in urine in workers producing two inorganic penta-
valent antimony compounds was measured in pre and post shift urine samples.
The regression equation for Sb in air and post-preshift Sb in urine was highly
significant (r = 0.86, p < 0.0001). This indicated that, on the average, an airborne
concentration of Sb in the order of 500 m g/m3 leads to an increase in urinary Sb
concentration of 35 m g Sb per g creatinine during the shift.
Following acute intoxication to antimony trichloride by inhalation of fumes, 7
workers were followed for symptoms and excretion of antimony. After 10 days no
antimony was detected in the urine (93).
Treatment with antimony as tartar emetic, in schistosomiasis thus may cause
the continued detection of antimony in urine 100 days after the final injection
(60).
In a human volunteer, labelled antimony (117Sb) was administered intravenously
as the chloride. At least two clearance components were found (90), with half-
times of 4 and 58 minutes.
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Table 6. Urinary and faecal excretion of Sb by rats given a single intravenous dose of
800 m g Sb/kg BW.
Hours after exposure Urine Faeces
m gSb % of dose m gSb % of dose
0-24 39.61 19.2 34.51 16.8
24-48 5.21 2.5 10.58 5.1
48-72 1.30 0.6 4.62 2.2
72-96 0.14 0.1 1.02 0.5
Sum  0-96 46.26 22.4 50.73 24.6
As given in ref. (6).
7.4.2 Clearance from the lungs
Inhalation of inorganic antimony Sb2Cl3 has been studied in rats. Twenty percent
of the body burden of Sb2C13 was retained in the lungs 4 days after exposure (23).
In Syrian hamsters antimony-tartrate-aerosols were rapidly cleared from the
lungs. Less than 1% of tri- and pentavalent antimony were observed 2 hours after
exposure (27).
7.4.3 Clearance from other organs
Pregnant BALB/c mice strain were fed arsenic or antimony (18.5 mega Bq/k
125Sb). After delivery, the offspring were transferred to normal mothers not fed
antimony or arsenic. The new-born mice then rapidly lost arsenic, but seemed to
retain antimony (29). Antimony was found in the new-born mice in the following
organs in decreasing order: Bone, skeletal muscle, spleen, heart, kidney, and lung.
After 50 days, 125Sb activity could only be demonstrated in muscle, skin and
spleen. Antimony seems to cross the placenta as readily as arsenic after injection,
but does so to a lesser extent if given in the diet. The content of radioactive
isotopes of arsenic and antimony both increased markedly in new-born mice
during nursing.
7.5 Relevant kinetic interactions
To date not documented in the literature.
8. Methods of Biological Monitoring
In general, uptake of a given chemical may be proportional to the exposure
concentration (25). This is, however, not necessarily the case with metal aerosols,
where two parameters make the situation different:
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1) Aerosols, of the same metal, can be of different aerodynamic diameters,
depending on the industrial process and hence deposition may vary in different
lung regions.
2) As opposed to organic volatile substances, solubility of antimony in the lungs
is limited, by change from one form of compound to the other. Several
considerations must be taken into account when conducting/selecting methods
for biological monitoring. For example it is important to consider: routes of
uptake; if excreted both in the urine and bile/faeces; difficulty to determine the
contribution of different routes to total uptake (air or food); if uptake is
dependent on the chemical form and differs between species.
The total body burden is often of special interest, and different biological
exposure indicators may reflect the body burden differently.
Neutron activation analysis (NAA) and atomic absorption spectrophotometry
(AAS) are the most important analytical methods currently used (see Section 6).
The detection limits expressed as mg/m3 are for airborne hydride stibine 0.001 by
inductively coupled plasma atomic emission spectroscopy (ICP-AES) and
0.00001 by ETAAS (41). The current method of choice for concentrations of
interest in industry is ICP-AES. This method has the advantage that several other
airborne hydrides, such as arsine, can be measured. Although ETAAS has a
higher degree of sensitivity only a single element can be determined per analysis.
X-ray spectrophotometry
Antimony trioxide dust in human lungs may be measured in vivo by X-ray
spectrophotometry (66, 67). The method depends on the absorption by dust
particles in the lungs of monochromatic X-rays having two alternative
wavelengths which lie on either side of the K critical wavelength of antimony. A
scintillation counter is mounted with the X-ray source giving in vivo
measurements of antimony dust exposure. The total X-ray dose that the worker
receives upon examination is one hundredth of the area dose of a normal chest X-
ray.
Human hair and lung tissue analysis by neutron activation analysis
Human hair may be used as a pollutant dosimeter for antimony exposure (2).
Neutron activation analysis (NAA) is the basis for analysis of hair from workers
exposed to many heavy metals. Hair samples are washed with acetone and water
according to IAEA procedures (International Atomic Energy Association). Scalp
hair is a rather strong adsorbent for heavy metals. NAA is especially suitable to
detect small quantities of other metals such as cadmium and mercury in hair.
A detection limit of 1.8 mg per kg lung tissue and concentrations of antimony
of 0.2 mg per kg in 0.5 g of dried biological samples have been reported with
these methods (103).
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Atomic-absorption-spectrophotometry (AAS)
Antimony levels in blood may be determined by hydride and electrothermal AAS
technique (63). Before measurements, blood and plasma samples were digested in
nitric acid. As antimony is mainly bound to erythrocytes, whole blood analysis is
recommended. The relatively low detection limit of 0.2-1.0 m g/1 indicates that the
method may also be used with non-exposed persons (103).
Another application of this method is for wet-oxidation of urine, followed by
extraction of metal chelates into an organic phase (89). The resulting phase is then
analysed by AAS. It is emphasised that nitric acid must be eliminated from the
wet-oxidation mixture because it results in incomplete recovery of antimony.
There is also a possibility of directly extracting antimony from urine followed by
AAS with carbon-rod atomisation. Smith and Griffiths (89) recommend this as the
preferred method for the analysis of urine samples from non-exposed individuals.
Both methods give reliable results up to 200 m g/1.
Cerumen analysis by atomic emission spectroscopy (AES)
Cerumen consists of the secretions of the sebaceous and ceruminous glands as
well as cell debris, which are similar material as found in sweat (49). Cerumen
may readily be harvested from workers with Q-tips, which are then treated with
nitric acid, heated and further processed for analysis. By contrast, non-exposed
individuals have antimony ranges of 13-72 m g/g in the cerumen. The plasma
levels were 0.0032 mg/1 - 0.054 mg/1 and the skin contained 0.03-0.22 m g/g.
9. Mechanisms of Toxicity
The effect of industrial dusts on activated alveolar macrophages has been studied
in rabbits (36). Macrophages were incubated with airborne dusts containing
different metals or Fe2O3. Hydrogen peroxide and superoxide anion radical release
from the macrophages were decreased by antimony dusts and other metal dusts
but not by Fe2O3. Phagocytising macrophages are important in pulmonary host
defence. Production and release of superoxide anion radicals are required for this
function. Decrease of superoxide anion radical production is associated with
decreased pulmonary host defence. Lung toxicity of antimony may be due to a
suppression of macrophage activity.
10. Effects in Animals and in Vitro Studies
10.1 Irritation and sensitisation
Antimony potassium tartrate, often called tartar emetic, is slowly absorbed by the
gastrointestinal tract, where it causes local irritation, resulting in vomiting (21).
Dermatological reactions to antimony trioxide on intact and non-intact skin
have not been observed in rats (strain information not given) (34). Inhalation of
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inorganic antimony compounds apparently does not cause irritation of the pulmo-
nary tissue, and is rapidly cleared from lung in rats (nose only exposure of female
albino rats - strain information not given) (23). Lipid pneumonia has been obser-
ved in rats and rabbits after exposure to antimony trioxide. The mechanism is not
understood but is thought to be due to the accumulation of highly irritating lipids
from successive disintegrating alveolar macrophages (possibly low-density lipo-
protein which can give rise to foam cells).
10.2 Acute toxicity
Antimony potassium tartrate, was estimated by Bradley and Frederick (12) to
have a minimum lethal oral dose for rats of 300 mg/kg BW (15).
Potassium antimony tartrate, given intraperitoneally as single doses of 2 mg or
20 mg/kg BW to adult male albino rats infected with Schistosoma mansoni
significantly increased the cerebral hemisphere acetylcholine content and reduced
the GABA content compared to controls (84). This effect may be the reason why
convulsions are observed in some patients on high doses of anti-parasitic
medication containing antimony.
Acute toxicity of different antimony compounds are shown in Table 7
expressed as LD50. The table indicates that antimony in the metal form is more
toxic than the tri- or pentavalent inorganic compounds. The tartrate, an organic
form of antimony, is highly toxic.
10.3 Short-term toxicity
Organic salts of antimony given to test animals (dog, rat) in therapeutic doses may
inhibit the contractility of the myocard, induce bradycardia and ST-segment
depression on the electrocardiogram (ECG). A dose of 30 mg of potassium
antimony tartrate per kilogram of heart weight, which corresponded to 10-15 mg
Sb/kg BW, was administered via the coronary circulation to isolated canine heart.
The dose given was comparable to the total dose given to humans as a cure for
schistosomiasis over 20 days. The ECG-changes may not be permanent, as other
studies have shown regression of the effects one month after exposure had ended.
The progressive decrease in contractile force was not reversible despite perfusion
with antimony-free oxygenated blood. Thus, some antimony may have been
bound to the myocardium after perfusion. A slight reduction in blood pressure
was also observed (14).
In a study where guinea pigs were exposed to 45.4 mg diantimonytrioxide/m3
for 33 - 609 hours, no morphological changes in the heart muscle were found on
microscopic or gross examination at autopsy (20). Neither did the authors observe
any ECG changes.
Mice given potassium antimony tartrate (5 ppm) in drinking water showed
about the same prevalence of fatty degeneration of the liver compared to control
mice fed drinking water without antimony (88).
15
Table 7. Mortality (LD50) from acute oral exposure to different compounds of antimony
(mg of antimony per kg BW).
Compound Rats Guinea pigs
Potassium antimony-trioxidetartrate 11  15
Antimony (metal) 100 150
Antimony trisulfide 1000 NG*
Antimony pentasulfide 1500 NG
Antimony trioxide 3250 NG
Antimony pentoxide 4000 NG
*NG = Not given in study.
From ref. (62).
Different pentavalent antimony salts each given in the amount of 0.3 g/kg BW
to Wistar rats intraperitoneally each day for 30 days interfered with urine osmo–
lality. This suggests that there may be an effect on the action of the antidiuretic
hormone. The disturbance regressed after cessation of treatment. If a higher dose
was given, 2 g/kg of BW, signs of acute tubular necrosis were observed (95).
Pentavalent organic Sb, as sodium stibogluconate or meglumine antimoniate,
containing 300 or 900 mg Sb/kg/day, were given to albino rats of both sexes
intramuscularly for 30 days (3). The former dose is comparable to the daily dose
given to humans in the treatment of Leishmaniasis. A dose related reduction in
weight gain, haemoglobin and haematocrit, and raised white cell counts were
observed for both substances. Also biochemical signs of hepatotoxicity and
nephrotoxicity were observed.
Mice (B6C3F1) and rats (F344) were given antimony potassium tartrate (APT)
intraperitoneally (1.5 - 22 mg/kg BW in rats; 6 -100 mg/kg BW in mice) or in
drinking water (16-168 mg/kg BW in rats; 59 - 407 mg/kg BW in mice) in a
14 days study (21). APT was poorly absorbed and relatively non toxic orally, but
intraperitoneal administration increased mortality, reduced body weight, and
produced lesions in liver and kidney.
10.4 Long-term toxicity/carcinogenicity
In an inhalation study on guinea pigs the animals were exposed to fume of
antimony trioxide. The air concentration of antimony trioxide was 45.4 mg/m3.
Daily exposure of 2-3 hours per day for more than 2 months gave rise to
interstitial pneumonitis and fibrosis of the lungs. Increases in absolute liver
weight occurred after exposure for more than 4 weeks, due to fatty degeneration
(20).
Long-term pulmonary effects of antimony trioxide were also examined in a
study on rats and rabbits using inhalation and intratracheal instillation. In the
inhalation experiment average Sb2O3 dust concentration 89 mg/m3 (rabbit) and
100-125 mg/m3 (rat), particle size was 0.6 m m, and exposure period was 14,5 and
10 months. In the intratracheal experiments Sb2O3 doses were 12-125 mg and
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particle sizes <1.0 - 1.5 m m. Many animals died from pneumonia, and autopsy
showed alveolar macrophage reaction and interstitial fibrosis of the lungs. The
antimony content of the lungs was related to the length of exposure. The authors
argued that doses were so high that pulmonary overload occurred, and should not
be interpreted as indication of fibrogenic property (34).
Mice were given antimony potassium tartrate in drinking water at a dose of
5 ppm during their whole life (88). Survival and the tumour frequency were not
affected in treated mice compared with controls. There was no increase in the
number of benign or malignant tumours.
In a more recent study aimed at investigating vasomotor reactivity pregnant rats
were given antimony trichloride in drinking water (0.1 and 1 mg/dl) until 22 days
after delivery. Maternal rats had a smaller weight gain than controls (83). No
macroscopic teratogenic effects were observed in the offspring.
NIOSH raised concern in their criteria document from 1978 (54) due to an
alleged increase in the incidence of lung cancer in antimony smelter workers in
England. This concern was later investigated by Groth et al. in a carcinogenesis
assay in rats (Wistar derived, 90 males and 90 females per group) (35). The rats
were given Sb2O3 (time-weighted average 45 and 46 mg/m3) or antimony ore con-
centrate (mainly antimony trisulphide: time-weighted average 36 and 40 mg/m3)
with particle sizes of 1.23 or 2.22 (mass median diameter). They were exposed for
7 hours/day, 5 days/week for up to 52 weeks. Interstitial fibrosis was observed in
both exposure groups at the end of the exposure period, both among males and
females. Lung neoplasms were found in 19/70 (27%) of female rats exposed to
Sb2O3 and 17/68 (25%) of female rats exposed to Sb ore as compared to zero in
the control group (p<0.001 for both comparisons). Lung neoplasms were not seen
in male rats. The lungs of the treated male rats were found to contain higher
concentrations of antimony than female lungs. Thus the tumour response does not
appear to be a function of lung tissue concentration of antimony alone. Arsenic
was also found in the lungs, which was higher in rats exposed to Sb2O3 than to Sb
ore.
In a review of existing data on animal carcinogenicity from 1986 (26) only a
single thesis study by Watt (98) is reported. In this study female CDF-rats were
exposed to antimony trioxide at concentrations of 1.6 and 4.2 mg/m3 of Sb for
6h/day, 5days/week for one year, with a follow-up period for another year. There
was a higher than expected frequency of lung neoplasms after the cessation of
exposure, i.e. in 14 out of 18 rats in the high dose group compared with one in the
low dose group, and none in the control group.
IARC concluded in 1988 (42) that: There is sufficient evidence for the carcino-
genicity of antimony trioxide in experimental animals. There is limited evidence
for the carcinogenicity of antimony trisulphide in experimental animals.
Since then a paper describing two animal inhalation studies of antimony trioxide
has been published (71). Male and female Fisher rats, 50 animals per sex per
exposure group, were exposed to levels of 0, 0.25, 1.08, 4.92 and 23.46 mg/m3 for
6hr/day, 5 days/week for 13 weeks, followed by a 27 week observation period in
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the subchronic study. In the carcinogenicity study the exposure levels were 0.06,
0.51 and 4.50 mg/m3 for 12 months, with a 12-months follow-up period. The
group size was 65 animals. The mass median aerodynamic diameter was 3.05 and
3.76 m m , respectively. In the subchronic study corneal irregularities were
observed in about 30% of the animals. This effect was not dose related, and was
not confirmed in the chronic study, as the effect was also present among control
animals. In the subchronic study, alveolar macrophages, chronic interstitial
inflammation and interstitial fibrosis were seen more frequent in the group with
highest exposure. In the chronic study, these effects were also observed, and most
pronounced in the group with highest exposure. There was no difference in
survival or tumour frequency between exposed and controls. The authors discuss
possible explanations for the discrepancy between their study and the previous
two experimental carcinogenicity studies on antimony trioxide. Considering the
lung burden data available, the most likely explanation is said to be that the expo-
sure levels were in fact higher in the studies of Groth et al. (35) and Watt (98). It
is referred to the fact that lung burden overload may produce pulmonary tumours,
even from exposure to biologically relatively inactive chemicals, like titanium
oxide. In addition it may be argued that the number of animals was rather small in
Watt’s study. However, this can not be stated about the study of Groth et al.
10.5 Mutagenicity and genotoxicity
Gurnani et al. found that 1/50 to 1/20 of LD50 of antimony trioxide fed to male
white Swiss mice, induced chromosomal aberrations in bone marrow and sperm
head (37, 38). (For the calculations an LD50 of antimony trioxide >20.000 mg/kg
of body weight was used.) The frequency of chromosomal abnormalities induced,
in bone marrow preparations, was dependent of the dose given and the duration of
exposure (Table 8). The highest dose, given for the longest period, was lethal.
Effects on germ cells, indicated by sperm head abnormalities, were possible, but
differences did not reach the level of statistical significance.
Tri- and pentavalent oxides and chlorides of antimony were not mutagenic in
the Salmonella assay. In the short-term SCE assay the trivalent forms of antimony
were positive. In a DNA-damage test (”rec assay”) all but trivalent chloride was
strongly positive (52).
Swiss mice were given different concentrations (0.5 g to 1.5 g per kg BW) of
antimony trichloride orally in vivo (5). DNA fragments were observed in spleen
cells in the high dose group, only.
Cultured human leucocytes were incubated with antimony sodium tartrate
(2.3 .10-9 M) for 48 hours to determine toxicity as decreased mitotic index (74).
The tartrate salt caused a statistically significant increased (p<0.05) number of
chromosome breaks (12% of the cells compared with 2% among controls).
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Table 8. Bone marrow chromosomal aberrations (CA) observed in male mice exposed to
antimony trioxide.
Days admini-
strated
No. of animals Dose (mg/kg BW/d) Percentage of CA
(gaps excluded)
Breaks/cell
7 5 Control 1.4 0.010
5 400 2.2 0.018
5 666.67 3.4 0.022
5 1000 9.6 0.074
(p <0.001*) (p<0.001*)
14 5 Control 1.6 0.010
5 400 3.2 0.022
5 666.67 4.0 0.026
5 1000 10.2 0.086
(p <0.001*) (p<0.001*)
21 5 Control 1.6 0.010
5 400 4.6 0.026
5 666.67 4.8 0.040
5 1000 # #
NS NS
*Values determined by a one-tailed trend test. NS = not statistical significant
#Dose was lethal.
As given in ref. (37).
10.6 Reproductive and developmental toxicity
Pregnant ewes given trivalent antimony potassium tartrate (2 mg/kg BW)
throughout pregnancy gave birth to lambs without any sign of disease (43).
In a more recent study aimed at investigating vasomotor reactivity pregnant rats
were given antimony trichloride in drinking water (0.1 and 1 mg/dl) until 22 days
after delivery (83). No macroscopic teratogenic effects were observed.
Le Blanc and Dean concluded in a study from 1984 that fathead minnow
embryos hatched normally in the presence of solutions saturated with antimony
trioxide at concentrations as high as 7.4 m g/l (56).
In a review article written by Winship in 1987, he concluded that animal studies
on teratogenicity of antimony were not positive (103).
10.7 Other studies
No data found.
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11. Observations in Man
11.1 Acute effects
The symptoms of acute oral antimony poisoning are similar to those of arsenic
poisoning, i.e. abdominal pain, vomiting, diarrhoea, dehydration and muscular
pain (91). Shock may be a striking feature of acute intoxication. Trivalent
antimony is more toxic than the pentavalent form. Haemoglobinuria occurs and
may lead to anuria and also uraemia. Hepato- and splenomegaly have also been
reported.
Five of seven men accidentally exposed to fume of antimony chloride
developed gastrointestinal disturbances. Urinary antimony estimations revealed
concentrations of more than 1.0 mg/l (93). Environmental measurements sugges-
ted that they were briefly exposed to 73 mg/m3 antimony expressed as the metal.
Cordasco et al. reported that pulmonary oedema occurred due to antimony
exposure from the work environment (18). They observed three cases of antimony
pentachloride reactions which induced varying degrees of bronchopulmonary
damage subsequent to a malfunction of reactors. Two of the patients subsequently
died. Further data on the dose of exposure were not given.
At an antimony plant in Little Rock, USA, X-ray examination of the lungs
conducted on six workers who were acutely ill after heavy exposures (2-12 hours)
to smelter fumes, all showed definite pneumonitis extending fanwise from each
hilus (80). A subsequent survey of exposure was done. The measurements
probably did not reflect the level occurring under heavy exposure conditions
producing acute pulmonary illness. The concentration range of air-borne
antimony in the breathing room samples from the electric furnace area was 0.92 -
70.7 mg/m3 with a mean of 10.1 mg/m3.
A case of acute antimony intoxication in a woman has been reported (6). The
24 year old woman was admitted to hospital one hour after the voluntary
ingestion of an unknown quantity of a powder containing antimony trisulphide
meant for veterinary use. At admission clinical examination showed not
abnormalities, except for complaints of slight epigastralgia and dysphagia
combined with a metallic taste in the mouth. No clinical signs of intoxication
were observed. Blood levels of antimony rapidly reached 5.1 m g/1. After less than
a day, the level was decreased to 2.0 m g/l. Levels in the bile were initially
measured to be l4 mg/1 and thereafter decreased gradually.
Another case report describes four persons who ate a cake prepared with
potassium antimony tartrate instead of cream of tartar (sic!). It was recalculated
that about 6 g was used in preparing the cake. One person died of severe gastric
bleeding, cardiogenic shock and anuria (55).
In 1774, a doctor requested ”James powder” from his apothecary. The drug
consisted of antimony oxide and potassium tartrate, and was usually given as an
emetic (69). The doctor persuaded the apothecary to give him three doses of this
powder, purportedly to alleviate the "headache, kidney trouble and fever" of the
doctor. Each dose of the powder contained 66 mg of antimony. The medical
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doctor subsequently died of the severe gastrointestinal effects due to the antimony
compound.
The use of old porcelain has caused accidental poisoning. The mechanism has
been thought to be release of antimony from porcelain through the action of acidic
drinks (4).
11.2 Effects of repeated exposure on organ systems
Except for data on the determination of concentration of antimony in different
tissues after industrial exposure, human data on the effects of antimony are few
(91). For instance, data on the effects of antimony gas (stibine) are few, and even
in the lead-battery industries where stibine exposure may be found, only acute
effects on the pulmonary system are observed (19, 22, 41, 46).
Subacute or chronic poisoning causes headache, vomiting, coughing, joint and
muscular pain, sleeplessness, vertigo, and loss of appetite. Antimony produces
intestinal irritation more rapidly than arsenic (12, 85). Emesis is also more promi-
nent. Metallic antimony is considered most toxic, followed by trivalent and then
pentavalent antimony. Antimony sulphide is the least toxic of the antimony salts.
Data on sensitisation by antimony compounds in humans has not been found.
11.2.1 Skin
Papular eruptions have been described on the skin of antimony exposed workers.
The changes are termed "antimony spots". They may be preceded by an intense
itch. Later the skin changes become vesicular and pustular, and are considered as
a form of an occupational contact eczema. Such spots are found among persons
who have been exposed to antimony and its salts. The time to the appearance of
visible skin eruptions may vary considerably, between two days and three months
(92).
There are, however, also reports that antimony spots are not caused by anti-
mony but by arsenic trioxide (94).
The breaking of antimony ingots, and melting the pieces in a crucible in a
brazing rod manufacturing plant may cause dermatitis (101). An eruption of
follicular papules and pustules may be observed. The cause of the eruption is
probably due to the trioxide fumes from the melting of antimony.
Motolese et al. found contact dermatitis in enamellers and decorators in the
ceramics industry, some of whom had been exposed to antimony trioxide (70).
Painless ulcerations and perforation of the nasal septum have been reported in
antimony workers (65). One of the workers had worked only nine months in the
metal furnace. Arsenic in the antimony material was considered the causative
agent, as antimony probably does not have such a profound effect on the nasal
mucosa.
11.2.2. Eye
Optic atrophy with visual disturbances was described in two persons treated for
schistosomiasis after a course of injections with trivalent antimony compounds
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(28). The author discusses that the reaction may be due to the infection, and not
the treatment.
11.2.3 Respiratory system
Lobanova et al. found that 11% of workers in an antimony ore in Yakutia in
Russia had developed dust bronchitis, stage I within 4-10 year after the start of
exposure (61). A clinical diagnosis of bronchitis was recorded. However,
pneumoconiosis was not detected by X-ray examination of the chest. They
investigated 160 workers directly exposed to antimony dust and fumes and 67
control subjects (office clerks at the same factory). Eighty-one per cent of the
workers were men, and 58% were from 20-40 years of age. The amount of dust in
the working atmosphere was between 51.3 and 2280 mg/m3 (mean 500.3 mg/m3).
The content of antimony was 4.2 – 0.8 mg/m3, and the contamination with arsenic
was 0.57– 0.05 mg/m3. The degree to what the reported bronchitis is related to the
effects of arsenic and not antimony exposure alone, remains unsettled. Measure-
ments of lung function as FEV1 were not documented.
Antimony pneumoconiosis is similar in radiological appearance to other forms
of simple pneumoconiosis, siderosis or coal worker pneumoconiosis (67).
Laryngitis, tracheitis and pneumonitis have been reported in a group of 78 US
smelter workers exposed to trivalent antimony oxide with a work area mean
concentrations of antimony between 10 and 12 mg/m3 (80). The observations
have not been verified in more recent studies. Progressive massive fibrosis has not
been described in antimony workers. Respiratory disability is probably not caused
by exposure, although in a Yugoslavian study of 51 smelter workers 18% had
obstructive changes and 10% mixed restrictive-obstructive changes (77, 78).
Classification of the pneumoconiosis of the 51 workers was as follows: 67% as lp,
14% as 2p, 18% as 3p and 1% as 3pq (according to ILO classification). The
confounding effect on the obstructive changes from smoking is unsettled.
A study of antimony process workers at a plant near Newcastle, UK, showed
that 44 of 262 men examined had signs of simple pneumoconiosis on X-ray of the
lungs. There was a tendency towards a higher average lung antimony content in
workers with a longer period of employment in the industry (64). Among 113
antimony process workers from the same plant X-ray spectrophotometry of the
lungs were performed, to measure the lung burden of antimony. Chest radio-
graphs were available for 72 subjects. The amount of antimony in the lungs
ranged from nil to just over 11 mg/cm2. There was a significant association
between employment duration and lung antimony content. There was an increase
in the radiographic category (according to the ILO classification) with increasing
length of employment, and also a linear relationship between lung antimony
measurements and radiographic category. McCallum later reported (65) that work
environment measurements in the 1980’s were around the OEL of 0.5 mg/m3, but
in personal samples the concentrations might exceed the OEL. The hygienic stan-
dards had been greatly improved over the last 20 years.
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11.2.4 Gastrointestinal tract
Pentavalent antimony has been implicated in the development of gastrointestinal
symptoms, including diarrhoea, occurring 15-20 days or longer after exposure
(80). There was also a detectable concentration of arsenic in the work room
atmosphere in this study.
Loss of appetite was the primary complaint after long term exposure of miners
(82).
11.2.5 Cardiovascular system
Antimony is considered to be cardiotoxic. This was one of the reasons why
antimony emetics (antimony sodium tartrate) were abolished. Sodium antimonyl
gluconate used for the treatment of schistosomiasis, was given for 6 days at
300 mg daily caused ECG changes in a ten year-old boy (85). The ECG changes
were accompanied by Stokes-Adams attacks, convulsions and runs of ventricular
extrasystoles.
In a review article it was suggested that the use of antimony in industry may
cause cardiovascular disease (10). In an old study of workers involved in the
industry manufacturing grinding wheels, it was reported that 6 out of 125
workers, exposed for eight months to two years, died due to sudden cardiac arrest,
whereas during 16 years before the use of antimony in the same plant only one
worker had died (13). A cohort age effect cannot be ruled out, thus, any
estimation of coronary heart risk from antimony exposure is not possible.
On the contrary, McCallum reported that male antimony workers in the
Newcastle factory had lower or equally observed levels of deaths from heart
disease compared to expected values in the region. The values in the age-groups
0-44, 45-64, and 65+. were found to be 2.0 (obs.) versus 1.99 (exp.), 7.0 versus
10.73, and 5.0 versus 5.15, respectively (65).
A study (87) of 1014 workers from an antimony smelter in Texas, USA, em-
ployed between 1937 and 1971, reported mortality from ischaemic heart disease.
Using different comparison populations, no differences reached statistical signi-
ficance.
In an epidemiological review of the relationship between the work place and
cardiovascular disease and mortality, antimony was listed as a probable causative
agent for arrhythmias and direct myocardial injury (50, 51).
11.2.6 Musculoskeletal system
Pains in the joints of patients treated with sodium antimony tartrate occurring near
the end of a two-week long treatment is common. These pains may also be felt
after chronic exposure to antimony-containing dusts. Acute arthritis has been
reported in wrist, knee and ankle joints, but these are less common than pain in
joints (103).
11.3 Genotoxic effects
Data have not been found.
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11.4 Carcinogenic effects
Mortality data of the workers at the factory in Newcastle have been reported in
various forms. Without giving any numbers, McCallum states that there was a
statistically significant increase among antimony process workers up until 1960,
but no increase for men first employed after this year (65). Doll reported preli-
minary data from the same study. Thirty-one deaths of lung cancer vs. 16.7
expected occurred among men exposed before 1961(24). In a later paper 32
deaths from lung cancer vs. 14.7 expected were reported for workers exposed
before 1961, and followed up for the period 1961 - 1992 (45). The increased
incidence of lung cancer reported was so large that the confounding effect of
smoking was ruled out as explaining the large risk increase. For workers exposed
after 1960, 5 vs. 9.2 expected cases were observed. The fall in risk has been
attributed to improved working conditions. Arsenic, however, an accepted cause
of lung cancer, was present in the work atmosphere up until 1960.
Wester et al. concluded multifactorial causes are responsible for the observed
excess mortality from lung cancer in smelter workers (100).
A mortality study of 1014 workers from an antimony smelter in Texas, USA,
employed between 1937 and 1971 (87) reported lung cancer and heart disease
data. Smoking, but no other confounders for exposure data were reported. A
standardised mortality ratio (SMR) of 1.39 (90% CI 1.01-1.88) for lung cancer
was reported, and there was a significant positive trend with increasing duration
of employment.
Gerhardsson et al. conclude after further studies of smelter workers in 1993 that
the excess of lung cancer is not exclusively caused by antimony exposure but
confounded by the presence of other metals and smoking (31). The results from
the US smelter workers study (87) strengthen this conclusion.
In a recent review on the incidence of cancer among workers involved in the
glass industry a clear increasing trend of the development of colon cancer was
observed, though the exposure also included other trace elements (102). The
exposure was divided into three categories of no, small amounts, or large amounts
of the metal. The odds ratio related to colon cancer for antimony increased from
1.4 through 1.8 to 5.0, respectively, the last values being statistically significant at
the 0.05 level. A more detailed documentation of the exposure level was not
given.
In 1989, before the two recent studies mentioned above were published, an
evaluation made by IARC (42) concluded as follows: ”There is inadequate evi-
dence for the carcinogenicity of antimony trioxide and antimony trisulphide in
humans. There is sufficient evidence for the carcinogenicity of antimony trioxide
in experimental animals. There is limited evidence for the carcinogenicity of anti-
mony trisulphide in experimental animals. Antimony trioxide is possibly carcino-
genic to humans (group 2B). Antimony trisulphide is not classifiable as to its
carcinogenicity to humans (group 3)”.
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11.5 Reproductive and developmental effects
In a metallurgical plant 318 female workers (compared to 115 controls) had a
higher incidence of menstrual disorders and abortions than females without
exposure to antimony (9). The control population consisted of female employees
not engaged in antimony production and handling, i.e. office workers. Women
exposed to antimony dusts had 3.4% premature births (1.2% in controls) and
12.5% spontaneous abortions (4.1% in controls).
The mean levels of antimony compounds in their blood were reported to be
53 mg/l versus 3 mg/l in controls. Urine levels among the exposed were 29 mg/l
(not detectable in controls). The investigators also followed up new-born children
of these women. The groups consisted of 70 children from exposed mothers and
20 children from controls. The birth weights for these two groups did not differ
(3360 g of 3350 g). At 3, 6 and 12 months the children of exposed mothers
(6300 g, 7460 g and 8960 g) had lower body weights than the children of non-
exposed mothers (6410 g, 7950 g and 10050 g) (t-tests of difference at 2.6, 3.3
and 5.7, i.e. with p<<0.05, respectively). The quality of this paper has seriously
been questioned (7). The number of birth effects among controls seems too low,
information bias is to be expected, and also confounding due to different socio-
economic status.
12. Dose-Effect and Dose-Response Relationship
12.1 Single/short-term exposure
Pentavalent organic antimony, as sodium stibogluconate and meglumine anti-
moniate given intramuscularly, were both shown to retard the growth rate and
cause hepatic enzyme elevations in rats. The range and severity of the toxic
reactions increased with dose, and there was adverse effects at the lowest dose of
300 mg Sb per kg per day (3).
In contrast, antimony potassium tartrate was shown to be non-toxic in mice,
whereas a dose-related toxicity occurred in rats, measured as mortality, retarded
growth rate and increased hepatotoxicity (21). Male rats showed increased morta-
lity at a daily dose of 24 mg per kg for 90 days. Lowered body weight was also
observed at the same exposure level. The liver effects were observed for both
sexes at a daily level of 6 mg per kg.
The chromosome study of Gurnani et al. (37) gives a no observable effect level
of less than 400 mg/kg antimony trioxide per day. The outcome is chromosomal
breaks, which may be of some relevance to the carcinogenic risk.
12.2 Long-term exposures
Table 9 shows adverse health effects after inhalation exposure to antimony dust.
Acute pulmonary effects were reviewed in paragraph 11.1 (80), while chronic
effects were reviewed in paragraph 11.2. At levels of exposure to antimony from
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Table 9. Reported level of inhalation exposure of antimony producing adverse health
effects in workers.
Response Exposure level in air (mg/m3) Ref
Acute pneumonitis 0.9 - 70.7 (80)
ECG-changes 0.58 - 5.5 (most>3.0) (13)
Pneumoconiosis >0.5 (64, 65)
0.58 to 5.5 mg/m3, with a mean greater than 3.0 mg/m3, 37 of 75 workers had
altered ECG´s and seven deaths due to cardiac disease was suspected (13). The
effects observed may in part have been caused by presence of arsenic in the dust,
and other exposures are poorly documented. Consequently, this study cannot be
used to set a NOAEL.
There are indications of a dose-effect relationship between quantity of anti-
mony and the degree of pneumoconiosis found on chest X-rays (64). However,
the lack of exposure data from the smelter industry does not allow a relevant
dose-effect relationship estimation. The exposure levels probably may have been
well above the OEL in the UK of 0.5 mg/m3, as McCallum states in 1989 that
”until recently it has been impossible to maintain this TWA consistently
throughout the process”. At this level, however, antimony spots are rare, and
routine chest radiography has shown a fall in the prevalence of simple
pneumoconiosis to less than 4% (65). Pulmonary fibrosis has also been studied in
the animal model. The number of alveolar macrophages was increased after 1
year of inhalation exposure to 0.06 mg/m3 antimony trioxide, but there were no
cases of interstitial fibrosis, not even in the higher exposure groups (0.51 and
4.5 mg/m3) . Signs of chronic pulmonary inflammation were observed both in the
exposure and control groups (71).
The problem of combined exposures to antimony and arsenic is present when
carcinogenic risk is to be evaluated from epidemiological studies. Although an
increased risk of lung cancer has been reported both in the mining and smelting of
antimony, exposure data are insufficient to establish a dose-effect relationship
from human studies concerning a carcinogenic effect. Earlier animal experiments
in rats gave an indication of a carcinogenic risk (35), however this was not
confirmed in later experiments (71).
13. Previous Evaluations by (Inter)National Bodies
The US Department of Health, Education, and Welfare issues a series of
occupational criteria documents through the National Institute for Occupational
Safety and Health (NIOSH). The first American maximum allowable concen-
tration for antimony dust and fumes was recommended by ACGIH in 1947 to be
0.1 mg/m3 without any justification in scientific studies. An occupational expo-
sure limit of 0.5 mg/m3 was later set based on animal studies. and a NIOSH report
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covering antimony was published in 1978 (54). It was concluded that ”based on
data which indicate that exposure to antimony may cause cardiac and respiratory
changes and irritation of the skin and mucous membranes” an OEL of 0.5 mg/m3
is proposed. It is further summarised that ”some data on antimony workers raise
the possibilities of respiratory and carcinogenic effects; however these hazards
ascribed to antimony have not been confirmed”.
The International Agency for Research on Cancer, IARC, has reviewed the
evidence for carcinogenicity of trace elements. The study on antimony and anti-
mony compounds from 1989 concludes that antimony trioxide is carcinogenic in
animals, and possibly carcinogenic in humans, whereas antimony trisulfide is not
classifiable as to carcinogenicity in humans (42).
The British Health and Safety Executive recently published a thorough criteria
document, concluding that cancer is the critical health effect, proposing a maxi-
mum exposure limit of 0.5 mg/m3 (7).
14. Evaluation of Human Health Risks
14.1 Groups at extra risk
From the available information no groups extra vulnerable to antimony exposure
can be identified.
14.2 Assessment of health risks
Industrial exposure to antimony compounds may give rise to the following health
hazards:
•  Lung oedema as acute effects of exposure to pentavalent antimony (18).
However, data on the doses were not given in the two fatal cases of antimony
pentachloride intoxication.
•  Respiratory symptoms; tracheitis, laryngitis and pneumonitis, may develop after
exposure to Sb2O3 (80). The concentrations found in the breathing zone in the
smelter building ranged from 0.9 to 70.7 mg/m3, with a mean of 10.8 mg/m3,
i.e. giving little information on threshold values for this exposure related
irritative respiratory effects. There was also substantial amounts of arsenic in
the air.
•  Pneumoconiosis following chronic exposure to trivalent antimony oxide dust
(65).
•  Cutaneous reactions after exposure to antimony, antimony salts (70) or
antimony trioxide (92).
•  Lung cancer has been suspected after prolonged exposure to antimony
containing dust (103). The contamination with arsenic compounds may be a
confounder, especially in the less well documented Russian studies on high
exposure levels of workers. This suggests that caution must be exercised
regarding the potential carcinogenicity of antimony. The general dust levels in
the Russian factories were extremely high and would alone cause respiratory
problems (61). Carcinogenicity studies in animals have given differing results
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(35, 71). A recent study of lung cancer in smelter workers suggests a multi-
factorial mechanism for lung cancer development in the smelter worker
environment, rather than a direct effect of antimony (31). This may in part settle
the disputes over the suspected cancer risk proposed by NIOSH and British
experts concerning observations in smelter workers up to 1970.
Clinical assessment of antimony compounds employed in the treatment of
parasitic diseases has provided toxicity information pertinent for other antimony
compounds used in industry. The case reports on adverse effects of anti-parasitic
drugs do not, however, yield dose-response data relevant for the occupationally
observed quantities of antimony. Further assessment of the health risks of
occupational use of antimony compounds, including the gaseous form stibine, has
to be collected from controlled animal studies together with continued emphasis
on follow-up of cohorts of antimony smelter workers as in the studies by
Gerhardsson et al. (30, 31).
14.3 Scientific basis for an occupational exposure limit
The critical doses given in Table 10 are based on effects documented in the
literature. These effects are not always of a very precise nature, partly because the
effects are common in all work environments, as mucosal irritation, and partly
because antimony compounds are often accompanied by other potentially noxious
agents, as arsenic.
Table 10. Reported LOAEL and critical effect in humans of some antimony compounds
as documented in the literature*.
Compound LOAEL Critical Effect Ref
Antimony trioxide >>0.5 mg/m3 Transitory lung X-ray deposits (80)
Antimony pentoxide ND Pain in muscles and joints during
therapeutic use
(80)
Antimony trisulfide 0.6 mg/m3 T-wave changes in ECG and gastric
bleeding
(13)
Antimony smelter dust ** Pneumoconiosis (17)
Antimony smelter dust 0.5 mg/m3 Pneumoconiosis, lung cancer (45, 65)
*The level of other metals in the work environment of the studies cited, among others arsenic and
zirconium, may have contributed in an unknown manner to the levels given here as critical. A
work environment without these confounders is, however, hardly seen in industry. Brieger et al’s
observations (13) should be interpreted with special caution.
ND = not documented.
**Several measurements reported: 0.081 - 0.95, 1.0-9.8, 11-75 and 138 mg/m3. No relation to
cases given.
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Antimony trioxide exposure below 0.5 mg/m3 has not been shown to give rise
to pulmonary changes observed on lung X-rays, whereas transitory skin ulcera-
tions may be observed where Sb2O3 dust penetrates sweat ducts (92) (94). This
level thus may not exclude such skin reactions.
Antimony pentoxide is still in therapeutic use in the treatment of schisto-
somiasis, and in pharmacological doses gives rise to acceptable and reversible
adverse effects.
The data on exposure in industry of antimony trisulphide on humans are few
and not sufficient to set a critical dose (40). There are reports on acute, severe
toxicity at concentrations of 5 mg/m3, but the importance of particle size is not yet
resolved.
The currently recommended occupational exposure limit according to different
national bodies is 0.5 mg/m3 in the working atmosphere. This level has some
support from the old study of Renes (80) and the accidental poisoning study of
Taylor (93). At this level it is suggested that, at most, only a very small permanent
accumulation of antimony would occur in the body, and it is believed that this
level as a time-weighted average concentration limit, should protect against the
pneumoconiosis, dermatitis, mucous membrane irritation, and ECG changes
reported at higher doses of antimony compounds in work air.
At a level of 0.5 mg/m3 or lower there is apparently no increased risk of
pneumoconiosis or lung cancer (45, 65).
15. Research Needs
There is at present a lack of studies concerning the genotoxicity and also the
carcinogenic potential of antimony. The exclusion of or interaction with common
contaminants in antimony ore, such as arsenic, which in combination with
antimony may be carcinogenic, would be of great concern in the evaluation of
such studies (1). Experimental studies should address possible mechanisms of
genotoxic effects.
It would be advantageous to establish working co-operation with the occu-
pational health services of Russian factories concerned with the use of antimony.
Studies on these cohorts of both men and women workers would probably give
important, more reliable, and purportedly, new information (9, 61).
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16. Summary
Berg JA, Skyberg K. 123. Antimony. The Nordic Expert Group for Criteria
Documentation of Health Risks from Chemicals. Arbete och Hälsa, 1998;11:1-37.
Antimony is an elementary metal mined mostly as antimony sulphide, and has
two valencies, 3+ and 5+. Antimony in the trivalent form is used as grid alloy in
storage batteries, cable sheaths in soldering flux and as pigment in paints. Modern
use is especially based on the properties as a flame retardant and semi-conductor.
Pentavalent antimony is still used as an anti-parasitic medication.
Industrial exposure may give rise to irritation of the respiratory tract, and cause
pneumoconiosis after long term exposure. This development may be unfavourably
influenced by smoking. The development of lung cancer in antimony smelter
workers is multi-factorial, but seems well documented in workers exposed prior to
1960. Animal studies on cancer risk have been contradictory.
Cardiovascular effects have been demonstrated in workers after high exposure.
Even some fatalities are documented for humans.
Contact dermatitis may develop in workers in contact with antimony containing
dusts.
Acute parenteral symptoms include gastrointestinal pain with vomiting and
diarrhoea.
Key words: Antimony, carcinogenicity, dermatitis, genotoxicity, lung cancer,
occupational exposure, pneumoconiosis, toxicity.
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17. Summary in Norwegian
Berg JA, Skyberg K. 123. Antimony. The Nordic Expert Group for Criteria
Documentation of Health Risks from Chemicals. Arbete och Hälsa, 1998;11:1-37.
Antimon er et metallisk grunnstoff, som utvinnes mest i form av antimon sulfid.
Det har to valenser, +3 og +5. Metallet brukes i blybatterier, kabelforinger, i
loddefluks og som malingpigment. Moderne bruk baserer seg særlig på antimons
flammehindrende og halvleder-egenskaper. Pentavalent antimon brukes som
middel mot parasittsykdommer.
Industriell eksponering kan gi irritasjon i luftveiene, som kan føre til en
sideroselignende pneumokoniose etter langtids eksponering. Denne utviklingen
fremmes av samtidig røyking. Utviklingen av lungekreft hos antimon produk-
sjonsarbeidere er sannsynligvis multifaktoriell, men synes nå vel dokumentert hos
arbeidere eksponert før 1960. Arbeidere som har startet sin eksponering seinere,
og hatt bedre arbeidsmiljøforhold, ser ikke ut til å ha økt risiko. Kreftrisiko
vurdert ved dyreforsøk har gitt motstridende resultater.
Effekter på hjerte-karsystemet av høy eksponering er vist hos arbeidere, med
noen dødsfall forårsaket av antimon trioksid.
Kontaktdermatitt var vanlig hos antimonarbeidere tidligere.
Akuttsymptomer ved forgiftning inkluderer gastrointestinale plager som diaré,
oppkast og buksmerter.
Nøkkelord: Antimon, dermatitt, genotoksisk effekt, karsinogen effekt, lungekreft,
pneumokoniose, toksisitet, yrkesmessig eksponering.
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In the search for literature the following data bases were used:
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 - Cancerline
 - Chemical abstracts
 - Medline
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 - Toxline
Submitted for publication June 17, 1998.
37
Appendix 1.
Permitted or recommended maximum levels of antimony (Sb)
Country ppm  mg/m3 Comments Year Ref.
Denmark - 0.5 1994 1
Finland - 0.5 1996 2
Germany 0.5 1997 3
- 5 30 min short-term
Iceland - 0.5 1989 4
Netherlands - 0.5 1997-1998 5
Norway - 0.5 1995 6
Sweden - 0.5 1996 7
USA (ACGIH) - 0.5 1997 8
(NIOSH) - 0.5 1997 9
(OSHA) - 0.5 1997 9
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